Specificity characteristics of 7 commercial creatinine measurement procedures by enzymatic and jaffe method principles by Roberts, William L. & Greenberg, Neil, Bachmann, Lorin M.
Clinical Chemistry 58:2 General Clinical Chemistry
391-401 (2012)
S p e c i f i c i t y  C h a r a c t e r i s t i c s  o f  7  C o m m e r c i a l  C r e a t i n i n e  
M e a s u r e m e n t  P r o c e d u r e s  b y  E n z y m a t i c  a n d  J a f f e  
M e t h o d  P r i n c i p l e s
Neil G reenberg,1* W illiam  L. Roberts,2 Lorin M . Bachmann,3 Elizabeth C. W rig h t,4 R. Neil D alton ,5
Jack J. Zakowski,6 and W . Greg M ille r3
b a c k g ro u n d : Standardized calibration does not change a 
creatinine measurement procedure’s susceptibility to 
potentially interfering substances.
m e th o d s : We obtained individual residual serum or 
plasma samples (n = 365) from patients with 19 differ­
ent disease categories associated with potentially inter­
fering substances and from healthy controls. Addi­
tional sera at 0.9 mg/dL (80 ju,mol/L) and 3.8 mg/dL 
(336 ju,mol/L) creatinine were supplemented with ace- 
toacetate, acetone, ascorbate, and pyruvate. We mea­
sured samples by 4 enzymatic and 3 Jaffe commercially 
available procedures and by a liquid chromatography/ 
isotope dilution/mass spectrometry measurement pro­
cedure against which biases were determined.
r e s u l t s :  The number of instances when 3 or more results 
in a disease category had biases greater than the limits of 
acceptability was 28 of 57 (49%) for Jaffe and 14 of 76 
(18%) for enzymatic procedures. For the aggregate group 
of 59 diabetes samples with increased 0-hydroxybutyrate, 
glucose, or glycosylated hemoglobin (Hb Alc), the enzy­
matic procedures had 10 biased results of 236 (4.2%) 
compared with 89 o f177 (50.3%) for the Jaffe procedures, 
and these interferences were highly procedure dependent. 
For supplemented sera, interferences were observed in 11 
of 24 (46%) of groups for Jaffe and 8 of 32 (25%) of 
groups for enzymatic procedures and were different at 
low or high creatinine concentrations.
c o n c lu s io n s :  There were differences in both magnitude 
and direction of bias among measurement procedures, 
whether enzymatic or Jaffe. The influence of interfering 
substances was less frequent with the enzymatic proce­
dures, but no procedure was unaffected. The details of
implementation of a method principle influenced its sus­
ceptibility to potential interfering substances.
© 2011 American Association for Clinical Chemistry
The 2006 report from the National Kidney Disease 
Education Program (NKDEP)' Laboratory Working 
Group (LWG) (1} highlighted the need for im­
proved standardization of routine measurements of 
serum and plasma creatinine (2, 3). Although cali­
bration was emphasized in the report, interference- 
related bias was not overlooked. In recommenda­
tions for in vitro diagnostics (IVD) manufacturers, 
the report stated, “IVD manufacturers must address 
analytical nonspecificity bias in current routine se­
rum creatinine methods.”
Standardization of creatinine measurement proce­
dures with calibrations traceable to isotope dilution mass 
spectrometry (IDMS) reference measurement proce­
dures has largely been accomplished for major manufac­
turers in North America, as evidenced in external quality 
assessment schemes using commutable samples. For ex­
ample, in the February 2010 College of American Pathol­
ogists (CAP) Creatinine Accuracy Calibration Verifica­
tion/Linearity (LN24) Survey, 11 method groups had 
mean bias of 0% (range —5.8% to 7.7%) vs NIST refer­
ence measurement procedure values for creatinine con­
centrations between 0.77 mg/dL (68 jumol/L) and 4.09 
mg/dL (362 ju,mol/L), and the CV for all participants (n = 
372) was between 6.6% and 2.9% (4 j .
The NKDEP LWG and the International Federation 
of Clinical Chemistry and Laboratory Medicine Working 
Group on Glomerular Filtration Rate Assessment de­
signed the present study to obtain contemporary data for
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Individual patient samples. The study was approved by 
the respective institutional review boards at both clin­
ical sample collection locations: Virginia Common­
wealth University (VCU) and University of Utah Asso­
ciated Regional University Pathologists (ARUP) 
laboratories.
Sample handling and storage conditions were con­
sistent with published information on stability of cre­
atinine in human serum or plasma (5). Individual pa­
tient serum or heparinized plasma samples were 
collected in accordance with standard laboratory prac­
tices. Residual samples submitted for laboratory testing 
were stored up to 8 h at room temperature then up to 
14 days at 2 -4  °C before division into aliquots and fro­
zen storage at — 70 °C (VCU) or up to 24 h at room 
temperature then up to 30 days at —20 to —30 °C be­
fore thawing, aliquoting, and refreezing at — 70 °C 
(ARUP). Five 0.25-mL aliquots, in 1.2-mL ciyovials 
(VWR International) were prepared from each resid­
ual sample and stored at <  — 70 °C until being shipped 
on solid C 0 2 to participating manufacturers and the 
designated comparison measurement procedure 
(DCMP) laboratory. Samples were stored at <  — 70 °C 
at each participating laboratory until being measured 
between January and March 2009.
We selected samples to obtain up to 20 individual 
serum or plasma samples in each of 19 disease cate­
gories established to have either known concentrations 
of, or a high probability to contain, substances sus­
pected as potential interferents in creatinine measure­
ment procedures (1). Samples were not pooled, except 
those with increased pyruvate were obtained from 
pooled whole blood that was incubated at room tem­
perature 24-48 h before centrifugation. We identified 
the selected samples in each category (Table 1) on the 
basis of previously measured laboratory values, patient 
location consistent with 1 or more of the selected dis­
ease categories, or medical record review. In addition, 
for a control group, we collected samples from 20 non­
diseased individuals (laboratory staff volunteers) who 
were not using any prescription or over-the-counter 
pharmaceutical or dietary supplement products.
Samples spiked with potential interfering substances. Se­
rum with a creatinine concentration of 0.90 mg/dL (80 
/i,mol/L) was obtained from a healthy male volun­
teer, age 48 years. Half was supplemented with a so­
lution of 150 mg/dL (13.26 mmol/L) creatinine hy­
use in establishing specificity performance recommenda­
tions for serum creatinine measurem ent procedures.
drochloride (Sigma Aldrich) dissolved in water to a 
final creatinine concentration of 3.80 mg/dL (336 
/j,mol/L). Candidate interfering substances were 
added as described in the Supplemental Data, which 
accompanies the online version of this article at 
http://www.clinchem.org/content/vol58/issue2.
INSTRUMENTS AND MEASUREMENT PROCEDURES
Designated comparison measurement procedure. We 
measured serum or plasma creatinine by liquid chro- 
matography/IDMS (LC-IDMS) based on the method 
described by Preiss et al. (6). Procedural details are 
provided in the online Supplemental Data.
Commercial clinical laboratory' measurement procedures. Par­
ticipating manufacturers and respective measurement 
procedures were as follows: Beckman Coulter Synchron 
Unicel enzymatic (El) and Jaffe (JI), Ortho Clinical Di­
agnostics Vitros 5,1 FS Chemistiy System enzymatic (E2), 
Roche Diagnostics Integra enzymatic (E3) and Jaffe (J2), 
and Siemens Dimension RxL enzymatic (E4) and Jaffe 
(J3). Characteristics of the commercial creatinine proce­
dures, and details of the protocol for preanalytical sample 
handling and creatinine measurement at the participat­
ing manufacturers’ laboratories, are provided in on­
line Supplemental Table SI.
Characterization of additional analytes. Procedures for 
measurement of concentrations of additional analytes 
used for selection and characterization of patient samples 
were as described in Table 1, footnote a.
STATISTICAL PROCEDURES
For each commercial procedure and the DCMP, we 
used the mean of quadruplicate creatinine measure­
ments on each sample for all statistical analyses and 
comparisons.
For samples supplemented with interfering sub­
stances, we calculated percentage recovery as the creat­
inine concentration at each concentration of the inter- 
ferent divided by the creatinine concentration of the 
unspiked sample, multiplied by 100. Percentage bias 
was the percentage recovery minus 100. We used stan­
dard linear or polynomial regression to estimate the 
relationship between percentage recovery of creatinine 
and the concentration of an interferent.
For individual patient samples, we calculated bias 
as the difference from the DCMP creatinine concentra­
tion. On the basis of the distribution of biases observed 
for the samples from healthy controls (Fig. 1, A and B), 
the criteria for presence of a nonspecificity bias was 
defined as the larger of 0.10 mg/dL (8.8 /j,mol/L) or 
10%. For the rationale for these criteria, see online Sup­
plemental Data: Additional Statistical Considerations.
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Table 1. Patient sample selection criteria for potential interfering substances.3
Median
creatinine.
Category Selection criteria Patient samples in the category mg/dL (range)b
Albumin, low Serum/plasma concentrations 1.4-4.0 mg/dL 
(median 2.0 mg/dL)
20 samples from 14 patients, 4 of whom had 3, 
3, 2, and 2 different samples each
0.82 (0.30-5.27)
p-Hydroxybutyrate Serum/plasma concentrations 33-103 mg/dL 
(median 64 mg/dL)
19 samples from 19 patients 0.89 (0.22-10.11)
Bilirubin, high Siemens Advia index 4; serum/plasma 
concentrations 9.3 mg/dL for 1 sample and 
15.6-37.1 mg/dL (median 32.5) for the remaining 
samples
20 samples from 5 patients, 2 of whom had 10 




Outpatient cardiac care clinics; with hypertension 
and taking 3 or more HTN/CVD medications'-
20 samples from 20 patients 1.35 (0.56-4.48)
Cephalosporins Patients receiving cefepime, ceftriaxone, cefazolin, 
cefoxitin, or cefpodoximed
20 samples from 19 patients, 1 of whom had 2 
different samples
0.76 (0.47-9.04)
Dialysis Blood collected immediately before hemodialysis 
procedure
20 samples from 20 patients 5.38 (1.50-11.33)
Dobutamine’' Patients receiving dobutamined 18 samples from 11 patients, 6 of whom had 3, 
2, 2, 2, 2, and 2 different samples each
1.96 (0.66-2.96)
Dopamine1' Patients receiving dopamined 11 samples from 6 patients, 3 of whom had 3, 
3, and 2 different samples each
2.19(0.55-2.61)
eGFR, low eGFR 15-30 mL • min^1 • (1.73 n f r 1 19 samples from 18 patients, 1 of whom had 2 
different samples
3.02 (2.15-4.24)
Glucose, high Serum/plasma concentrations 388-816 mg/dL 
(median 455)
20 samples from 18 patients, 2 of whom had 2 
different samples
1.10(0.34-2.83)
Hb A1r, high Plasma Hb A1r concentrations 8.1 %—13.2% (median 
8.9%); glucose concentrations 77-461 mg/dL 
(median 261)
20 samples from 20 patients 0.83 (0.64-2.03)
Hemolyzed Siemens Advia index 4; approximate serum/plasma 
hemoglobin concentrations 350—>1000 mg/dL 
(median 450)
20 samples from 18 patients, 1 of whom had 2 
different samples, and 1 of whom had a second 
sample in the high urine protein group
0.88 (0.46-8.35)
Kidney transplant Patient status posttransplant, taking 1 or more 
immunosuppressant drugs (tacrolimus, sirolimus, 
cydosporine, mycophenolic acid)
20 samples from 20 patients 1.31 (1.00-2.94)
Lidocaine Serum/plasma concentrations 0.3-10.8 mg/L 
(median 4.3)
20 samples from 20 patients 0.79(0.49-6.10)
Lipemic Siemens Advia index 2-3, approximate 
serum/plasma triglycerides 500-1000 mg/dL based 
on intralipid equivalents
20 samples from 15 patients, 2 of whom had 4 
and 3 different samples each
1.39(0.21-4.99)
Protein, high Serum/plasma concentrations 6.9-17.9 mg/dL 
(median 10.4)
20 samples from 20 patients 0.99(0.51-1.88)
Protein, low Serum/plasma concentrations 3.1-6.2 mg/dL 
(median 4.2)
20 samples from 20 patients 1.02 (0.34-4.72)
Protein, urine, 
high
Urine albumin 226 and 547 mg/L (n = 2), albumin- 
creatinine ratio 2983 mg/g (n = 1), urine protein 
between 3.1 and 21.8 g/L (n = 15)
18 samples from 15 patients, 2 of whom had 2 
different samples, and 1 of whom had a 
second sample in the hemolyzed group
2.94 (0.97-7.95)
Pyruvate Pooled heparinized blood at room temperature for 
24-48 h, plasma concentrations 0.19-0.34 mmol/L 
(median 0.29)
20 different pooled samples 1.16 (0.77-2.28)
■ Albumin, glucose, and total protein in serum/plasma samples were measured by use of a Vitros 5,1 FS Chemistry System (Ortho Clinical Diagnostics). 
0-Hydroxybutyrate was measured by use of Liquicolor reagent (Stanbio Laboratory) on a Cobas c501 analyzer (Roche Diagnostics). Bilirubin, hemolysis, and lipemia 
indexes were estimated by use of a Siemens Advia 1650 analyzer (Siemens Medical Solutions Diagnostics). Bilirubin concentrations were measured by use of the
Siemens Advia procedure. Approximate hemoglobin concentrations were based on index values from Ortho Vitros and approximate triglyceride values on index 
values from Siemens Advia. eGFR was calculated with the IDMS traceable MDRD Study equation with creatinine measured by use of Roche enzymatic Creatinine
Plus reagents and Calibrator for Automated Systems adapted to a Siemens Advia 1650 analyzer. Hb A, r was measured by use of phenylboronic add affinity HPLC
procedure (Trinity Biotech), lidocaine by use of an Abbott TDx analyzer (Abbott Laboratories), urine albumin and protein by use of a Siemens Advia 1650 analyzer, 
and pyruvate by use of a spectrophotometric procedure with lactate dehydrogenase and NADH ( 19). 
b Measured by LC-ID-MS/MS.
r Hypertension (HTN)fcardiovascular disease (CVD) medications included diuretics, vasodilators, calcium channel blockers, 0-blockers, angiotensin-converting 
enzyme inhibitors, angiotensin II receptor antagonists, 3-hydroxy-3-methylglutaryl-coenzyme A-reductase inhibitors (statins), or other cholesterol-reducing agents 
and platelet aggregation inhibitors. 
d Samples were obtained during the drug-dosing interval when patients were expected to be at steady state. 
p Two patients received both dopamine and dobutamine.
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Fig. 1. Creatinine measurement bias vs DCMP for individual serum or plasma samples from the apparently healthy 
control group (A and B), the hemolyzed group (C and D), and the delayed separation group (E and F).
Note that 1 sample with creatinine 8.35 mg/dL is not shown in C but had biases of 0.10, -0.02, -0.28, and -0 .56 for 
procedures E3, E4, E2, and E1, respectively, nor in panel D but had biases of 0.20, 0.20, and 0.14 mg/dL for procedures J1, J2, 
and J3. Symbols: A , procedure E1 or J1; □ , procedure E2 or J2; O, procedure E3 or J3; x ,  procedure E4. The lines indicate the 
criteria used for a meaningful nonspecificity bias. Multiply by 88.4 to convert creatinine to /nmol/L.
Results
CALIBRATION TRACFABIIJTY
We assessed trueness for each creatinine measurement 
procedure by recovery ofthe certified concentration with
or without expanded uncertainty for NIST Standard Ref­
erence Materia] (SRM) 967 Creatinine in Frozen Human 
Serum (7) (online Supplemental Fig. S3). The DCMP 
method results (mean and expanded uncertainty) were 
0.751 (0.029) mg/dL [66.4 (2.6) /nmol/L] and 3.850
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Table 2. Maximum percentage bias observed for serum supplemented with potential interfering substances.
Creatinine measurement procedure, maximum bias, %
Substance E1 E2 E3 E4 J1 J2 J3
Acetoacetate 174 mg/dL
Creatinine 0.9 mg/dL 1.9 2.1 - 0 .5  - 0 .2  122 -4 3 .9  27.2
Creatinine 3.8 mg/dL 30.9 -0 .1  -1 1 .3  5.5 4.7 - 0 .6  - 0 .7
Acetone 100 mg/dL
Creatinine 0.9 mg/dL - 1 .9  -0 .1  - 0 .8  - 0 .8  28.3 20.5 30.3
Creatinine 3.8 mg/dL 7.5 - 0 .8  6 8.3 2.2 0.1 - 0 .6
Ascorbate 20 mg/dL
Creatinine 0.9 mg/dL -1 2 .4  0 -1 1 .6  - 9 .6  7.7 86.1 177.4
Creatinine 3.8 mg/dL 2.5 - 5 .7  13.3 42.3 - 5 .4  - 6 .8  0
Pyruvate 1.2 mmol/L
Creatinine 0.9 mg/dL - 1  0.2 0.5 - 2  54.7 40.2 50.2
Creatinine 3.8 mg/dL 14.1 - 0 .4  7.3 11.5 0.8 - 1 .7  0.4
(0.081) mg/dL [340.4 (7.2) /nmol/L] for the 2 concentra­
tions, and were within the SRM uncertainty intervals. In 
addition, Community Bureau of Reference Certified Ref­
erence Materials 573, 574, and 575, Human Serum, were 
included in all runs for the DCMP. See online Supple­
mental Tables S2 and S3 for additional data on the cali­
bration traceability of the DCMP.
For the commercial procedures, bias was ^5.9% 
for SRM 967-1 and <3.8% for SRM 967-2. Four of 7 
means were within the uncertainty interval of SRM 
967-1 (see online Supplemental Fig. S3A). The ±2 SD 
ranges for 2 means overlapped the uncertainty interval, 
and the ±2 SD range for 1 mean (procedure E4) was 
just outside the uncertainty interval. For SRM 967-2 
(see online Supplemental Fig. S3B), 3 of 7 means were 
within the uncertainty interval, the ±  2 SD ranges for 3 
means overlapped the uncertainty interval, and the ±  2 
SD range for 1 mean (procedure El) was just outside 
the uncertainty interval.
For all commercial procedures, mean biases for 
137 of 140 results (98%) in the healthy individuals were 
within 0.10 mg/dL (8.8 /nmol/L) of the DCMP (Fig. 1, 
A and B), and the mean biases for each individual pro­
cedure ranged from —5.5% to 5.8%, further support­
ing calibration traceability to IDMS reference measure­
ment procedures (8}. With either the mean bias with 
SRM 967-1 or the mean bias for healthy individuals, in 
conjunction with CV estimates based on either the 
within-procedure imprecision for SRM 967-1 obtained in 
this study or with the within-procedure/among- 
laboratories CV from the CAP Comprehensive Chemis­
try Survey C-B (2011), the total allowable error of all com­
mercial procedures was within the recommendations of 
the NKDEP LWG (1) (see online Supplemental Fig. S4).
Therefore, we used no corrections for calibration biases in 
any of the commercial procedures in the data analysis.
INTERFERING SUBSTANCES SUPPLEMENTED INTO SERUM
Owing to concerns about their stability, acetoacetate, 
acetone, ascorbate, and pyruvate were supplemented 
into serum with within-reference interval and in­
creased creatinine concentrations. The maximum per­
cent biases observed for each supplemented interferent 
at each concentration of creatinine are summarized in 
Table 2, and interferographs are shown in online Sup­
plemental Data Figs. S5-S8.
INDIVIDUAL SAMPLES FROM CLINICAL CATEGORIES
Difference plots for the biases observed between rou­
tine creatinine measurement procedures and the 
DCMP are shown for apparently healthy controls and 
hemolyzed and delayed sample processing (Fig. 1); in­
creased glucose, increased glycosylated hemoglobin 
(Hb Alc), and increased /3-hydroxybutyrate (Fig. 2); 
and low albumin, low total protein, and high total pro­
tein (Fig. 3) clinical sample categories. The biases ob­
served for the other clinical sample categories are 
shown in online Supplemental Figs. S9-S19.
Table 3 summarizes results for all clinical sample 
categories by measurement procedure. For 1 or more 
of the Jaffe procedures, ^ 3  biased creatinine values per 
clinical sample group were observed for the increased 
/3-hydroxybutyrate, increased glucose, increased 
Hb Alc, cardiovascular disease, cephalosporin, dobut- 
amine, lidocaine, increased bilirubin, delayed sample 
processing, hemolyzed, lipemic, low albumin, high to­
tal protein, and post-kidney transplant groups. For 1 
or more of the enzymatic procedures, ^ 3  biased creat-
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Fig. 2. Creatinine measurement bias vs DCMP for individual serum or plasma samples from the groups with 
increased glucose (A and B), increased Hb A1c (C and D), and increased /3-hydroxybutyrate (E and F).
Note that 1 sample with creatinine 10.11 mg/dL is not shown in panel E but had biases of 0.39, -0.31, -0.48, and -0 .96 
for procedures E2, E3, E4, and E1, respectively, nor in panel F but had biases of 0.33, 0.02, and -1 .27 mg/dL for procedures 
J3 ,11 , and 12 . A, procedure E1 or 11 ; □ , procedure E2 or 12; O, procedure E3 or J3; X, procedure E4. The lines indicate the 
criteria used for a meaningful nonspecificity bias. Multiply by 88.4 to convert creatinine to /u,mol/L.
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Fig. 3. Creatinine measurement bias vs DCMP for individual serum or plasma samples from the low albumin group 
(A and B), the low total protein group (C and D), and the high total protein group (E and F).
A , procedure E1 or J1; □ , procedure E2 or J2; O, procedure E3 or J3; x ,  procedure E4. The lines indicate the criteria used for 
a meaningful nonspecificity bias. Multiply by 88.4 to convert creatinine to ju,mol/L.
inine values per clinical sample group were observed 
for the increased j8-hydroxybutyrate, dobutamine, li- 
docaine, increased bilirubin, hemolyzed, lipemic, and 
high total protein groups. Of the 365 clinical samples, 
the overall proportion of biased results was 11.7%, 
9.0%, 8.8%, and 11.2% for the 4 enzymatic methods
and 19.5%, 15.6%, and 35.9% for the 3 Jaffe methods. 
Overall, more biases were observed for the Jaffe proce­
dures, but findings were inconsistent in terms of occur­
rence rate, direction, and magnitude of bias (Table 3, 
Figs. 1-3, and online Supplemental Figs. S9-S19), 
within a method principle (Jaffe or enzymatic).
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Table 3. Number of samples in each sample category with a negative ( - or positive (+ ) bias >0.10 mg/dL
(>8.8  /umol/L) or >10%, whichever was greater.
Creatini ie  measurement procedure
E1 E2 E3 E4 J1 J2 J3
Sample category n - + - + - + - + - + - + - +
Apparently healthy 20 0 1 0 0 0 0 0 0 0 0 1 0 0 1
Clinical categories 365 31 12 6 27 21 11 33 8 1 70 39 18 3 128
Diabetes mellitus
0-Hydroxybutyrate 33-103 mg/dL 19 0 0 0 3 0 1 0 0 0 11 5 1 0 14
Glucose 388-816 mg/dL 20 1 2 0 1 1 0 0 0 0 14 0 8 0 19
Hb Au  8.1 %—13.2% 20 0 0 0 0 0 0 1 0 0 1 0 0 0 16
Cardiovascular disease with hypertension 20 0 0 0 0 0 0 0 0 0 0 1 0 0 6
Drugs
Cephalosporins 20 0 0 0 0 0 0 1 0 0 5 1 0 0 10
Dobutamine 18 3 0 1 0 2 0 2 0 0 3 0 0 0 7
Dopamine 11 0 0 0 0 0 0 0 0 0 0 0 0 0 1
Lidocaine 20 0 10 0 11 0 9 0 8 0 4 4 0 0 5
Endogenous substances
Bilirubin 9-38 mg/dL 20 13 0 1 0 10 0 18 0 0 0 19 0 0 3
Delayed separation 24-48 h 20 0 0 0 0 0 0 0 0 0 13 0 3 0 8
Hemolysis, hemoglobin >350 mg/dL 20c 11 0 2 0 0 1 6 0 0 6 0 5 2 0
Lipemia 20 2 0 1 1 8 0 5 0 1 2 4 1 0 8
Protein abnormalities
Albumin 1.4-4.0 g/dL 20 0 0 0 0 0 0 0 0 0 2 2 0 1 7
Protein 7-18 g/dL 20 1 0 0 8 0 0 0 0 0 7 2 0 0 17
Protein 3.1-6.2 g/dL 20 0 0 0 1 0 0 0 0 0 1 1 0 0 2
Kidney disease
Predialysis 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0
eGFR 15-30 mL-min 1 -(1.73 m2) 1 19 0 0 1 1 0 0 0 0 0 1 0 0 0 1
Post-kidney transplant 20 0 0 0 0 0 0 0 0 0 0 0 0 0 4
Urine protein 3-22 g/L (n = 15) 18 0 0 0 1 0 0 0 0 0 0 0 0 0 1
Discussion
Calibrations of the LC-IDMS DCMP and the com­
mercial measurement procedures were verified to be 
traceable to Joint Committee for Traceability in Lab­
oratory Medicine (JCTLM) listed reference mea­
surement procedures and reference materials. Con­
sequently, calibration bias of the commercial 
creatinine measurement procedures was not a factor 
in evaluating the influence of potential interfering 
substances.
The serum creatinine concentration influenced 
the magnitude of specific interferences in our supple­
mentation studies. The interferographs, particularly 
for the Jaffe procedures, demonstrated substantial in­
terferences at low creatinine concentrations but no in­
terference at high creatinine concentrations. Nearly all 
of the interferences observed for the Jaffe procedures 
were positive, with the exception of acetoacetate for 
procedure J2. The magnitude of the interference ob­
served for the Jaffe procedures was similar for acetone 
and pyruvate but differed markedly for acetoacetate 
and ascorbate.
For enzymatic procedures, the magnitude of the 
interference observed in the supplementation studies 
was generally smaller than for the Jaffe procedures, but 
the pattern of interference across procedures was more 
complicated. For acetoacetate, the interference was 
positive for 1 enzymatic procedure, negative for 1, and 
absent for the other 2. No interference was observed for
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acetone with any of the enzymatic procedures. For 
ascorbate, 2 enzymatic procedures showed negative in­
terference at low creatinine concentrations and 2 
showed positive interference at high creatinine concen­
trations. Procedure E3 showed negative interference at 
low creatinine concentrations and positive interference 
at high creatinine concentrations. For pyruvate, 2 pro­
cedures showed positive interferences at high creati­
nine concentrations.
Cobbaert et al. (9) examined the effects of albu­
min, hemoglobin A, IgG, and unconjugated bilirubin 
on enzymatic and Jaffe creatinine procedures by sup­
plementing these substances into serum pools. Those 
authors found positive creatinine biases from albumin 
and IgG for Jaffe procedures but not for enzymatic pro­
cedures. An important difference in our experimental 
design was that we selected individual clinical samples 
containing the potentially interfering substances. 
However, biases may have been due to presence of the 
substance used to select the samples or to unknown 
substances associated with samples in that disease cate­
gory. We found that 2 of 3 Jaffe procedures exhibited a 
positive bias with high protein samples and a few sam­
ples had a negative bias with 1 Jaffe procedure; we also 
observed a positive bias with 1 enzymatic procedure. 
Our findings for patient samples selected for low albu­
min concentrations showed that 1 Jaffe procedure had 
a positive bias with 2 samples, 1 Jaffe procedure had a 
negative bias with 2 samples, and 1 Jaffe procedure had 
a negative bias with 1 sample and a positive bias with 7 
samples. For the high total protein sample category, 1 
enzymatic and 2 Jaffe procedures showed positively bi­
ased creatinine values. Although we were not able to 
specifically identify the interfering substances in the 
clinical samples, our results for samples with protein 
concentrations not within reference intervals demon­
strated that both enzymatic and Jaffe methods were 
affected and that the influence of interfering substances 
was complex and dependent on the technical imple­
mentation of a measurement procedure.
Previously reported effects of bilirubin on enzy­
matic and Jaffe procedures for serum creatinine have 
been contradictory. Cobbaert et al. (9) found that en­
zymatic and some Jaffe procedures demonstrated sim­
ilar slight positive or negative interferences with un­
conjugated bilirubin, whereas other Jaffe procedures 
exhibited >10% negative interference. Owen et al. 
(10) measured creatinine results for 73 patient samples 
with bilirubin concentrations of 5.8-56 mg/dL (99­
958 /i,mol/L) using Roche enzymatic and Jaffe proce­
dures and an LC-IDMS procedure. They found that 
49% of creatinine results had —10% to —35% bias for 
the enzymatic procedure and, for the Jaffe procedure, 1 
result had >10% bias and 2 results had <  — 10% bias. 
For the high bilirubin patient group in our study, all
but 1 sample had bilirubin concentration >19 mg/dL 
(>325 /i,mol/L), and most of these samples were col­
lected from only 3 patients. For 3 of 4 enzymatic pro­
cedures and 1 of 3 Jaffe procedures, a large portion of 
the samples were negatively biased. Interestingly, pro­
cedure E2 had only 1 biased result and procedure Jl 
had no biased results with the increased bilirubin sam­
ples. As for protein, our results demonstrated that the 
influence of bilirubin was complex and dependent on 
the technical implementation of a measurement 
procedure.
Delayed separation of serum from cellular compo­
nents following specimen collection has been reported 
to cause increased creatinine results with some Jaffe 
creatinine procedures, likely owing to accumulation of 
pyruvate (11). For the delayed sample separation cate­
gory, all 3 Jaffe procedures showed a positive bias with 
variable numbers of samples. When serum pools were 
supplemented with pyruvate, all 3 Jaffe procedures 
demonstrated positive biases at a creatinine concentra­
tion of 0.9 mg/dL (80 /j,mol/L) but almost no bias at 
creatinine 3.8 mg/dL (336 /j,mol/L); 2 of 4 enzymatic 
procedures had positive biases only at the higher creat­
inine concentration.
Highly procedure-dependent interferences were 
observed for the aggregate of 3 sample categories with 
59 diabetes patient samples known to have increased 
j3-hydroxybutyrate (n = 19), glucose (n = 20), and 
Hb Alt (n = 20). All 3 Jaffe procedures had a large 
number of positively biased results for the glucose cate­
gory. Procedures Jl and J3 had a large number of pos­
itively biased results for the j3-hydroxybutyrate cate­
gory, whereas procedure J2 had a smaller number of 
predominantly negative biases. Procedure J3 had a 
large number of positive biases for the increased Hb A, t 
category, and the other Jaffe procedures had essentially 
no biases. For the enzymatic procedures, there were 
0-3  samples with biases in each of the diabetes sample 
categories, suggesting minimal or no specificity issues 
for these categories. Our data do not identify the root 
cause for a given bias (e.g., Hb Alt is likely not the root 
cause of the bias in the increased Hb A, t patient group), 
but these disease categories likely included additional 
substances that influenced some creatinine proce­
dures. For patients with diabetes, enzymatic proce­
dures appeared to be more suitable than Jaffe 
procedures.
In the cardiovascular disease group, only the J3 
procedure showed positive biases. For the kidney dis­
ease patient categoiy, none of the procedures had bi­
ased results for the sample categories predialysis, low 
estimated glomerular filtration rate (eGFR), and high 
urine protein where creatinine concentrations were 
higher. For the post-kidney transplant group with 
lower creatinine concentrations, only procedure J3 had
Clinical Chemistry 58:2 (2012) 399
a few positively biased results. For the patient groups 
for which creatinine is an important biomarker, it ap­
pears that properly implemented enzymatic or Jaffe 
procedures gave satisfactory results.
Iidocaine showed large positive biases in a large 
number of samples for all enzymatic methods, whereas 
Jaffe methods had modest biases in a few samples. 
There was no influence from dopamine. Dobutamine 
showed positive biases with 2 of 3 Jaffe procedures and 
negative biases with all enzymatic procedures. Cepha­
losporin showed positive biases for 2 of 3 Jaffe proce­
dures, with no influence on the enzymatic procedures.
REVIEW OF FINDINGS VS MANUFACTURERS’ LABELING
We compared the biases for samples containing known 
amounts of supplemented interfering substances to in­
terference claims obtained from each manufacturers 
instructions for use (IFU). In general, the IFUs did not 
contain adequate information regarding the effects of 
interfering substances on the procedures. Acetoacetate, 
acetone, ascorbate, and pyruvate are well-known inter- 
ferents in creatinine measurements (12}. Nonetheless, 
only 4 of 7 IFUs had interference claims for acetoace­
tate, none had claims for acetone, 5 had claims for 
ascorbate, and 2 had claims for pyruvate. Of those that 
did have claims for these interferences, most did not 
have adequate information to interpret the claims. In 
many cases, the IFUs did not state the concentrations of 
interfering substances and/or creatinine concentra­
tions tested. In some cases in which the concentration 
of interferent was stated, it was substantially lower than 
that expected to be encountered in diseased patient 
populations (12-17). In addition, the criteria used for 
evaluation of the effects of interferences were not uni­
form among manufacturers.
STRENGTHS AND LIMITATIONS
Strengths of this investigation were inclusion of a sub­
stantial number of individual patient samples repre­
senting diverse clinical conditions selected to have a 
high probability to contain potentially interfering sub­
stances and a control group of samples from healthy 
individuals. This approach eliminated any noncom- 
mutability artifacts from influencing results and in­
cluded a range of both exogenous pharmaceutical and 
endogenous metabolic substances. Several labile meta­
bolic substances were examined by supplementing a 
single donor serum to ensure the substances were pres­
ent in the samples tested. The LC-IDMS DCMP and 
the commercial measurement procedures were vali­
dated to have calibration traceable to JCTLM listed ref­
erence measurement procedures. IDMS technology is 
considered the best available to be free from the influ­
ence of interfering substances. All measurements were
made in quadruplicate to minimize the influence of 
measurement imprecision.
Limitations of this study were that we were unable 
to include all manufacturers because of limited vol­
umes available (as residual samples from clinical labo­
ratories). The clinical samples were selected to have a 
high probability to contain various interfering sub­
stances; however, the identity and concentrations of 
the substances responsible for a given interference were 
either unknown or only partially known based on the 
selection parameters. In addition, the number of sam­
ples included in each clinical category was relatively 
small (approximately 20), and in some cases, different 
samples from the same individual were included more 
than once in a clinical category. The clinical samples 
were not handled uniformly before aliquoting and 
freezing, with variable time spent at room temperature, 
refrigerated, or frozen, with possible metabolic changes 
or loss of labile components (e.g., dopamine and do­
butamine). In addition, samples collected at ARUP 
were thawed, aliquoted, and refrozen. Given previously 
published findings that creatinine in serum or plasma 
is a stable measurand under common sample storage 
conditions (5 j, it is unlikely that sample handling or 
storage contributed to underestimation of creatinine in 
this study. However, the consequence of sample han­
dling and storage variations on substances that may 
interfere with creatinine measurements is unknown, 
and may have led to underestimation of bias in certain 
disease categories. Finally, the serum creatinine con­
centration interval examined in the patient samples se­
lected for this study was inadequate to address mea­
surement specificity issues at creatinine concentrations 
typically found in pediatric patients between the ages of
2 months and 10 years, in whom values are usually 
<0.6 mg/dL (50 jxmol/L) (18).
Conclusions
Overall, the influence of interfering substances was less 
frequent with enzymatic procedures than with Jaffe 
procedures, but no procedure was unaffected by the 
interfering substances or disease categories examined. 
There were differences in both magnitude and direc­
tion of bias among measurement procedures within a 
given method principle, enzymatic or Jaffe, indicating 
that influence of interfering substances depended on 
details of implementation of the method principle. 
With the exception of the diabetic disease category, 
which showed substantially more frequent influence of 
interfering substances with Jaffe procedures than with 
enzymatic procedures, no general conclusions regard­
ing Jaffe or enzymatic technologies can be drawn. Sup­
plemented interferents had greater influence at creati­
nine concentrations within reference intervals than at
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higher concentrations, highlighting the importance of 
evaluating interference at more than 1 concentration of 
the measurand. The results emphasize the need to eval­
uate interference characteristics in detail with each par­
ticular measurement procedure with consideration of 
the patient populations served.
Manufacturers’ labeling and claims for interfer­
ences with commercial creatinine measurement proce­
dures had shortcomings in the information provided. 
It is recommended that manufacturers’ claims be based 
on testing at clinically relevant concentrations of a 
broad range of potential interferents as well as at 2 or 
more concentrations of the measurand.
On the basis of the magnitude of biases observed in 
the healthy controls category, it is recommended that 
specifications for bias from interfering substances in 
creatinine measurement procedures should not exceed 
the larger of 0.1 mg/dL or 10% at a given concentration 
of creatinine.
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